239 related articles for article (PubMed ID: 15768377)
21. The efficacy and tolerability of candesartan cilexetil in an elderly hypertensive population.
McInnes GT; O'Kane KP; Jonker J; Roth J
J Hum Hypertens; 1997 Sep; 11 Suppl 2():S75-80. PubMed ID: 9331015
[TBL] [Abstract][Full Text] [Related]
22. Candesartan cilexetil. A review of its use in essential hypertension.
McClellan KJ; Goa KL
Drugs; 1998 Nov; 56(5):847-69. PubMed ID: 9829158
[TBL] [Abstract][Full Text] [Related]
23. Clinical profile of the novel angiotensin II type I blocker candesartan cilexetil.
Sever PS
J Hypertens Suppl; 1997 Dec; 15(6):S9-12. PubMed ID: 9493121
[TBL] [Abstract][Full Text] [Related]
24. Switch from ABCD pretreatment to A-II-A treatment: a multinational, open, centrally randomized, prospective parallel group comparison.
Asmar R; Porcellati C; Dusing R
Drugs Exp Clin Res; 2004; 30(4):153-61. PubMed ID: 15553661
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics and pharmacodynamics of candesartan cilexetil in patients with normal to severely impaired renal function.
Buter H; Navis GY; Woittiez AJ; de Zeeuw D; de Jong PE
Eur J Clin Pharmacol; 1999 Feb; 54(12):953-8. PubMed ID: 10192757
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics and antihypertensive effects of candesartan cilexetil in patients undergoing haemodialysis: an open-label, single-centre study.
Schulz EG; Bahri S; Schettler V; Popov AF; Hermann M
Clin Drug Investig; 2009; 29(11):713-9. PubMed ID: 19813774
[TBL] [Abstract][Full Text] [Related]
27. Candesartan cilexetil: an angiotensin II receptor blocker.
Stoukides CA; McVoy HJ; Kaul AF
Ann Pharmacother; 1999 Dec; 33(12):1287-98. PubMed ID: 10630830
[TBL] [Abstract][Full Text] [Related]
28. Acute and 3-month treatment effects of candesartan cilexetil on hemodynamics, neurohormones, and clinical symptoms in patients with congestive heart failure.
Mitrovic V; Willenbrock R; Miric M; Seferovic P; Spinar J; Dabrowski M; Kiowski W; Marks DS; Alegria E; Dukát A; Lenz K; Arens HA
Am Heart J; 2003 Mar; 145(3):E14. PubMed ID: 12660683
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetic properties and bioequivalence of candesartan cilexetil in Korean healthy volunteers.
Jeon JY; Im YJ; Kim Y; Han SM; Jo MJ; Shin DH; Yoo JS; Moon BK; Kim BK; Lee BH; Choi YH; Cho BS; Jang HY; Chae SW; Kim MG
Drug Dev Ind Pharm; 2013 Sep; 39(9):1296-9. PubMed ID: 23030309
[TBL] [Abstract][Full Text] [Related]
30. Effects of candesartan cilexetil in patients with systemic hypertension. Candesartan Cilexetil Study Investigators.
Reif M; White WB; Fagan TC; Oparil S; Flanagan TL; Edwards DT; Cushing DJ; Michelson EL
Am J Cardiol; 1998 Oct; 82(8):961-5. PubMed ID: 9794352
[TBL] [Abstract][Full Text] [Related]
31. Fixed-dose combination therapy of candesartan cilexetil and amlodipine besilate for the treatment of hypertension in Japan.
Yasuno S; Fujimoto A; Nakagawa Y; Kuwahara K; Ueshima K
Expert Rev Cardiovasc Ther; 2012 May; 10(5):577-83. PubMed ID: 22651833
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics of candesartan cilexetil in patients with renal or hepatic impairment.
de Zeeuw D; Remuzzi G; Kirch W
J Hum Hypertens; 1997 Sep; 11 Suppl 2():S37-42. PubMed ID: 9331004
[TBL] [Abstract][Full Text] [Related]
33. Candesartan cilexetil: an angiotensin II-receptor blocker.
See S; Stirling AL
Am J Health Syst Pharm; 2000 Apr; 57(8):739-46. PubMed ID: 10786259
[TBL] [Abstract][Full Text] [Related]
34. A new approach to assessing antihypertensive therapy: effect of treatment on pulse pressure. Candesartan cilexetil in Hypertension Ambulatory Measurement of Blood Pressure (CHAMP) Study Investigators.
Asmar R; Lacourcière Y
J Hypertens; 2000 Nov; 18(11):1683-90. PubMed ID: 11081784
[TBL] [Abstract][Full Text] [Related]
35. A candesartan cilexetil/hydrochlorothiazide combination tablet provides effective blood pressure control in hypertensive patients inadequately controlled on monotherapy.
Campbell M; Sonkodi S; Soucek M; Wiecek A
Clin Exp Hypertens; 2001 May; 23(4):345-55. PubMed ID: 11349825
[TBL] [Abstract][Full Text] [Related]
36. Conversion of stable kidney transplant recipients from a twice daily Prograf-based regimen to a once daily modified release tacrolimus-based regimen.
Alloway R; Steinberg S; Khalil K; Gourishankar S; Miller J; Norman D; Hariharan S; Pirsch J; Matas A; Zaltzman J; Wisemandle K; Fitzsimmons W; First MR
Transplant Proc; 2005 Mar; 37(2):867-70. PubMed ID: 15848559
[TBL] [Abstract][Full Text] [Related]
37. A twelve-week, multicenter, randomized, double-blind, parallel-group, noninferiority trial of the antihypertensive efficacy and tolerability of imidapril and candesartan in adult patients with mild to moderate essential hypertension: the Iberian Multicenter Imidapril Study on Hypertension (IMISH).
Palma Gámiz JL; Pêgo M; Contreras EM; Anglada MP; Martínez JO; Esquerra EA; Sagastagoitia Gorostiza JD;
Clin Ther; 2006 Dec; 28(12):2040-51. PubMed ID: 17296460
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and tolerability of candesartan cilexetil in special patient groups.
Trenkwalder P
Blood Press Suppl; 2000; 1():27-30. PubMed ID: 11059633
[TBL] [Abstract][Full Text] [Related]
39. Antihypertensive efficacy of candesartan in comparison to losartan: the CLAIM study.
Bakris G; Gradman A; Reif M; Wofford M; Munger M; Harris S; Vendetti J; Michelson EL; Wang R;
J Clin Hypertens (Greenwich); 2001; 3(1):16-21. PubMed ID: 11416677
[TBL] [Abstract][Full Text] [Related]
40. Candesartan cilexetil: an update of its use in essential hypertension.
Easthope SE; Jarvis B
Drugs; 2002; 62(8):1253-87. PubMed ID: 12010090
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
